Subscribe Sign in

Business

Buy, hold, sell: CBA, BHP, CSL shares

1 min read Rewritten in plain language

Broker Notes

Show what we removed
  • S&P/ASX 200 Index shares hit a 15-week low before closing at 8,665 points on Friday, down 0.76% for the week.
  • Athanasiou has a buy rating on this ASX 200 healthcare share.
  • Immunoglobulin sales improved in the second half of fiscal year 2026 amid the company announcing a further share buy-back of $1.1 billion.
  • CSL shares have risen from $92.24 on June 3 to trade at $179.19 on September 24.

4 sentences from our version of the report, chosen to cover it. Nothing here is written; every line is in the article below. How

S&P/ASX 200 Index shares hit a 15-week low before closing at 8,665 points on Friday, down 0.76% for the week.

The report’s most important sentence, shortened and in plain words. How

Headline check

There is nothing in this headline a machine can check against the report: no figure, no name and no quotation.

Nothing was measured here, so nothing is claimed. How this is checked

Manns' superior seeds (15767599714) library picture
Not from this story. A library photograph of stock market trading screens, used to illustrate it. Manns' superior seeds (15767599714) Henry G. Gilbert Nursery and Seed Trade Catalog Collection.; J. Manns & Co. / Wikimedia Commons, CC BY

S&P/ASX 200 Index shares hit a 15-week low before closing at 8,665 points on Friday, down 0.76% for the week.

The CSL share price rose 0.77% last week to close at $176.95 on Friday.

Athanasiou has a buy rating on this ASX 200 healthcare share.

CSL's recovery is gaining momentum after forecasting underlying profit growth guidance of about 5 per cent in fiscal year 2027.

Immunoglobulin sales improved in the second half of fiscal year 2026 amid the company announcing a further share buy-back of $1.1 billion.

The outlook for this global health care company is improving after prolonged underperformance.

CSL shares have risen from $92.24 on June 3 to trade at $179.19 on September 24.

The Commonwealth Bank share price fell 1.05% last week to finish at $150.83 on Friday.

Shortened to 1 minute of reading, this version reads 10.6 on the Niral Score.

You are reading our version, not theirs. This is The Motley Fool Australia's report shortened to its most important sentences, in plainer words, with verdicts and loaded words taken out. Plain description stays, and so do adjectives that carry a fact, such as "former" or "federal". The reporting, the facts and the quotations are theirs — quotations are never edited — and the indicators beside it measure this version. Hover or tap Adjectives to see every one left in the text.

How outlets headlined it

Each outlet's own headline. Struck through: the loaded words our version leaves out. Plainest first.

  • The Motley Fool Australia Buy, hold, sell: CBA, BHP, CSL shares plain
  • The Motley Fool Australia Buy, hold, sell: Xero, South32, Woodside shares plain
  • The Motley Fool Australia Should I buy CBA shares in October? plain

How each outlet filed it

Outlet Niral ScoreAdjectivesSentimentHappiness
The Motley Fool Australiaas they published this story 14.9 11 0.1 56.4
The Motley Fool Australia 18.1 14 -0.0 39.4
The Motley Fool Australia 26.2 21 0.8 53.4
Mundane Readneutralized from The Motley Fool Australia 14.3 11 0.1 56.4

Sign in to react.

Comments

Nothing here yet.

Sign in to comment.

Questions

Readers can ask a question about this story here. Questions and answers are for subscribers. Sign in to read them.

Comments are read before they appear where anything in them needs a person to look. Nothing posted here is ever deleted; a comment taken down keeps its text and the reason, so the decision can be looked at again. How this works

The same event elsewhere

2 other outlets filed this story. The scoreboard above is what they did differently.